Monday, July 15, 2024

Pneumococcal Vaccine CAPVAXIVE™ Recommended by CDC Advisory Committee for Adults

Similar articles

The U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) has unanimously recommended Merck’s CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for pneumococcal vaccination. The recommendation applies to adults aged 65 and older, as well as adults aged 19 to 64 with certain risk conditions.

ACIP recommends a single dose of CAPVAXIVE for adults 65 years and older who have not previously received a pneumococcal conjugate vaccine or have an unknown vaccination history, adults aged 19-64 with underlying medical conditions or risk factors who have not previously received a pneumococcal conjugate vaccine or have an unknown vaccination history, and adults 19 and older who started their pneumococcal vaccine series with PCV13 but have not received all recommended PPSV23 doses.

CAPVAXIVE™ Shows Promise in Preventing Pneumococcal Disease in Adults Over 65

Shared clinical decision-making is advised for adults over 65 who have completed their vaccine series with both PCV13 and PPSV23. CAPVAXIVE is indicated for active immunization against invasive disease and pneumonia caused by Streptococcus pneumonia serotypes 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15B, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, and 35B in adults 18 years and older. The approval for preventing pneumonia is based on immune response data, with continued approval contingent upon confirmatory trials.

“CAPVAXIVE represents an innovative approach to preventing invasive pneumococcal disease in adults, specifically designed to protect against the strains causing severe disease in those 65 and older,” said Dr. Eliav Barr, senior vice president at Merck Research Laboratories. The ACIP recommendation highlights CAPVAXIVE’s clinical efficacy for adults in the U.S., awaiting final review by the CDC and the Department of Health and Human Services.


CAPVAXIVE™ Not Recommended for Those with Severe Allergies or Immunocompromised Patients

CAPVAXIVE should not be administered to individuals with severe allergic reactions to any component of the vaccine or diphtheria toxoid. Those with altered immunocompetence, including those on immunosuppressive therapy, may have a reduced immune response. Common adverse reactions in adults 18-49 include injection-site pain, fatigue, headache, myalgia, erythema, and swelling. In adults 50 and older, common reactions include injection-site pain, fatigue, and headache.

Merck, known as MSD outside the U.S. and Canada, aims to use leading-edge science to save and improve lives worldwide. With over 130 years of innovation, Merck continues to develop important medicines and vaccines, fostering a diverse and inclusive global workforce. Merck is dedicated to creating a safe, sustainable, and healthy future.


Resource: Merck, June 27, 2024

You can follow our news on our Telegram and LinkedIn accounts.

Subscribe to our newsletter

To be updated with all the latest news, offers and special announcements.

Latest article